Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' b... Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients' brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. 더 보기
– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – –...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced...
– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker – – ALTO-100 demonstrated a favorable...
– Despite its reported benefits for aspects of cognition, vortioxetine does not demonstrate greater clinical efficacy in major depressive disorder (MDD) patients with cognitive impairment– –...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.339 | -7.35517465828 | 4.609 | 4.8 | 4.19 | 335242 | 4.5026171 | CS |
4 | -0.04 | -0.92807424594 | 4.31 | 4.98 | 3.61 | 704373 | 4.21236821 | CS |
12 | -7.71 | -64.3572621035 | 11.98 | 15.04 | 3.61 | 803906 | 7.50705916 | CS |
26 | -7.99 | -65.1712887439 | 12.26 | 17.55 | 3.61 | 468162 | 8.28231763 | CS |
52 | -17.73 | -80.5909090909 | 22 | 24 | 3.61 | 372721 | 9.85341025 | CS |
156 | -17.73 | -80.5909090909 | 22 | 24 | 3.61 | 372721 | 9.85341025 | CS |
260 | -17.73 | -80.5909090909 | 22 | 24 | 3.61 | 372721 | 9.85341025 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관